Antibodies to lymphotoxin-alpha
AssigneeGenentech, Inc.
InventorsCamellia W. Adams, Jane L. Grogan, Austin L. Gurney, Krista McCutcheon
Life of this patent
Estimating the term…
Abstract
The invention provides various antibodies that bind to lymphotoxin-α, methods for making such antibodies, compositions and articles incorporating such antibodies, and their uses in treating, for example, an autoimmune disorder. The antibodies include murine, chimeric, and humanized antibodies.
Claims21
An isolated anti-lymphotoxin-α (LTα) antibody comprising:
- a light chain variable region wherein the complementarity-determining region (CDR)-L1 sequence is RASQAVSSAVA (SEQ ID NO:2), the CDR-L2 sequence is SASHRYT (SEQ ID NO:7), and the CDR-L3 is QEXYSTPWT (SEQ ID NO:11), wherein X is any amino acid;
- and a heavy chain variable region wherein the CDR-H1 sequence is GYTFTSYVIH (SEQ ID NO:16), the CDR-H2 sequence is YXXPYXAGTXYXEKFKG (SEQ ID NO:
- 101) wherein X is any amino acid;
- and the CDR-H3 sequence is PTMLPWFAY (SEQ ID NO:20).
A method of producing an antibody comprising:
- (i) culturing a host cell comprising nucleic acid encoding an anti-lymphotoxin-α (LTα) antibody comprising a light chain variable region wherein the complementarity-determining region (CDR)-L1 sequence is RASQAVSSAVA (SEQ ID NO:2), the CDR-L2 sequence is SASHRYT (SEQ ID NO:7), and the CDR-L3 sequence is QEXYSTPWT (SEQ ID NO:11), wherein X is any amino acid;
- and a heavy chain variable region wherein the CDR-H1 sequence is GYTFTSYVIH (SEQ ID NO:16), the CDR-H2 sequence is YXXPYXAGTXYXEKFKG (SEQ ID NO:
- 101) wherein X is any amino acid;
- and the CDR-H3 sequence is PTMLPWFAY (SEQ ID NO:20) under conditions to produce the antibody;
- and (ii) recovering the antibody.
A method of inhibiting lymphotoxin-α-activated cell proliferation, said method comprising contacting a cell or tissue with an effective amount of an anti-lymphotoxin-α (LTα) antibody comprising a light chain variable region wherein the complementarity-determining region (CDR)-L1 sequence is RASQAVSSAVA (SEQ ID NO:2), the CDR-L2 sequence is SASHRYT (SEQ ID NO:7), and the CDR-L3 sequence is QEXYSTPWT (SEQ ID NO:11), wherein X is any amino acid;
- and a heavy chain variable region wherein the CDR-H1 sequence is GYTFTSYVIH (SEQ ID NO:16), the CDR-H2 sequence is YXXPYXAGTXYXEKFKG (SEQ ID NO:
- 101) wherein X is any amino acid;
- and the CDR-H3 sequence is PTMLPWFAY (SEQ ID NO:20).
A method of treating an autoimmune disorder, wherein said autoimmune disease is selected from the group consisting of rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, lupus and graft-versus-host disease, in a subject in need thereof, comprising administering to the subject an effective amount of an anti-lymphotoxin-α (LTα) antibody comprising a light chain variable region wherein the complementarity-determining region (CDR)-L1 sequence is RASQAVSSAVA (SEQ ID NO:2), the CDR-L2 sequence is SASHRYT (SEQ ID NO:7), and the CDR-L3 sequence is QEXYSTPWT (SEQ ID NO:11), wherein X is any amino acid;
- and a heavy chain variable region wherein the CDR-H1 sequence is GYTFTSYVIH (SEQ ID NO:16), the CDR-H2 sequence is YXXPYXAGTXYXEKFKG (SEQ ID NO:
- 101) wherein X is any amino acid;
- and the CDR-H3 sequence is PTMLPWFAY (SEQ ID NO:20).
A method of treating rheumatoid arthritis in a subject in need thereof, comprising administering to the subject an effective amount of an anti-lymphotoxin-α (LTα) antibody comprising administering to the subject an effective amount of an anti-lymphotoxin-α (LTα) antibody comprising a light chain variable region wherein the complementarity-determining region (CDR)-L1 sequence is RASQAVSSAVA (SEQ ID NO:2), the CDR-L2 sequence is SASHRYT (SEQ ID NO:7), and the CDR-L3 sequence is QEXYSTPWT (SEQ ID NO:11), wherein X is any amino acid;
- and a heavy chain variable region wherein the CDR-H1 sequence is GYTFTSYVIH (SEQ ID NO:16), the CDR-H2 sequence is YXXPYXAGTXYXEKFKG (SEQ ID NO:
- 101) wherein X is any amino acid;
- and the CDR-H3 sequence is PTMLPWFAY (SEQ ID NO:20).
Dependencies are inferred from the claim text.